Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

2

(use as many sheets as necessary)

of

Complete if Known Application Number 10/697,563 Filing Date October 31, 2003 First Named Inventor **GUTHRIE** Art Unit NOT YET SPECIFIED Examiner Name **NOT YET SPECIFIED** Attorney Docket Number T00462-0003-WO-US

	U.S. PATENT DOCUMENTS							
Examiner Initials	Cite No.1	Document Number Number Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
W		US- 4,591,600	05-27-1986	Creuzet et al.				
9		US- 5,855,892 -	01-05-1999	Potter et al.				
		US- 6,096,364	08-01-2000	Bok et al.				
		US- 6,239,114	05-29-2001	Guthric et al.				
		US- 6,251,400	06-26-2001	Guthrie et al.				
M		US- 20010055627A1	12-27-2001	Guthric et al.				
		US-						
		US-						
		US-						
		US-						
-		US-		<u></u>				
		US-						
		US-						
		US-						
		US-						
		US-	•					
		US-						
		US-						
		US-						
		US-						

FOREIGN PATENT DOCUMENTS							
Cite No.1	Foreign Patent Document			Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant	T
	Office:	Number ⁴	Kind ⁸ (if known)	MM-DD-YYYY	Applicant of Cited Document	Passages or Relevant Figures Appear	Τ ⁶
	wo	0062774	A1	10-26-2000	Shanahan		
	wo	0170029	Al	09-27-2001	Guthrie et al.		
	wo	02055071	Al	07-18-2002	Guthrie et al.		
							┷
	<u> </u>						\perp
				 .			+-
				·			_
						<u> </u>	+
	\vdash				 		+
		WO WO	Cite No.1 Office3 Number4 WO 0062774 WO 0170029	Foreign Patent Document	Foreign Patent Document Publication Date	Foreign Patent Document	Cite No.1 Office3 Number4 Kind5 (if known) Number4 No.1 Name of Patentee or Applicant of Cited Document Passages or Relevant Figures Appear WO 0062774 A1 10-26-2000 Shanahan WO 0170029 A1 09-27-2001 Guthric et al.

Examiner ,	0 0 0 0	, Date	
Signature \ \(\mathcal{U}_{\text{\text{\text{\text{Signature}}}} \)	O- Talkaldostts	Considered	2-22-06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Office, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTC/SB/08B (08-03)
Approved for use through 08/30/2008. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known			
				Application Number	10/697,563 October 31, 2003		
INF	DRMATION	1 DI	SCLOSURE	Filing Date			
STATEMENT BY APPLICANT				First Named Inventor	GUTHRIE		
017		J.,	AI I LIOAIII	Art Unit	NOT YET SPECIFIED		
(use as many sheets as necessary)				Examiner Name	NOT YET SPECIFIED		
Sheet	2	of	2	Attorney Docket Number	T00462-0003-WO-US		

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	_					
xaminer nitials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.						
(G)		ROBBINS, Effect of Flavonoids on Survival Time of Rats Fed Thombogenic or Atherogenic Regimens, Journal of Atherosclerosis Research, volume 7, 1967, pages 3-10, Elsevier Publishing Company, The Netherlands.						
		GUTHRIE et al, In Vitro Studies on Anti-Cancer and Cholesterol-Lowering Activities of Citrus Flavonoids and Ilinonoids", FASEB Journal, March 15, 2000, page A564: Abstract, vol. 14, Federation of American Societies for Experimental Biology, Bethesda, MD, USA.						
		KUROWSKA et al, Regulation of Lipoprotein Metabolism in HEPG2 Cells by Citrus Flavonoids", American Chemical Society, abstract, March 2000, vol. 219, The National Meeting, American Chemical Society, Washington, D.C., USA.						
		KUROWSKA et al, Hypolipidemic activities of tangeretin a flavonoid from tangerine in vitro and in vivo, Annual Meeting of the Federation of American Societies for Experimental Biology on Experimental Biology 2001, March 31-April 4, 2001, Abstract, Orlando, Florida, USA.						
		KUROWSKA et al., Tangeretin, a Citrus Flavonoid, reduces metabolic abnormalities associated with insulin resistance, FASEB Journal, March 20, 2002, page A648: Abstract, volume 16, Federation of American Societies for Experimental Biology, Bethesda, MD, USA.						
The		MERCK RESEARCH LABORATORIES, The Merck Manual of Diagnosis and Therapy, 1999, page 166 right-hand column, page 167 left-hand column line 4, Merck Research Laboratories, Whitehouse Station, N.J., USA.						
			+					

Examiner		Date		
Signature	co. 10 dd to	Considered	3.99-02	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed of form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.